Array BioPharma appoints vp of clinical development

Bengt Berstrom has joined biopharmaceutical firm Array BioPharma as vp of clinical development.

Bengt Berstrom has joined biopharmaceutical firm Array BioPharma as vp of clinical development.

With more than 17 years" working in the pharmaceutical industry, Dr Bergstrom will lead Array's clinical science and drug safety activities for its growing pipeline of targeted small molecule drugs to treat cancer and inflammatory diseases.

"Bengt's expertise in advancing cancer and inflammation therapeutics, including oral cancer therapies such as Xeloda, will be a competitive advantage for Array as we progress our five wholly owned drugs in human clinical development," said chief executive Robert Conway.

Prior to joining Array, Dr Bergstrom held various roles Hoffmann-La Roche, most recently as clinical science leader in oncology drug development.

Dr Bergstrom studied at the University of Lund in Sweden where he received his MD and PhD.




You may also like

Research & Development

Array BioPharma closes cancer drug deal with Pierre Fabre

Array may receive up to US$425m in agreement to develop novel oncology products
Regulatory

Anticancer agent – binimetinib

The new generation of genetically targeted anticancer agents is being developed for melanoma patients with specific mutations
Research & Development

Array Biopharma and Genentech to progress ChK-1 programme

Genentech will pay US$28m upfront payment to Array
Research & Development

Array BioPharma signs strategic oncology collaboration

Agreement with Novartis will advance aim to become integrated, commercial-stage biopharma company
You need to be a subscriber to read this article.
Click here to find out more.
Regulatory

UK clinical trial reforms come into force in largest regulatory overhaul in 20 years

The MHRA and Health Research Authority are implementing the most significant package of clinical trial regulatory reforms in more than two decades, introducing faster assessment routes for lower-risk trials and mandatory registration of trial results
Research & Development

Epitopea receives MHRA approval for first-in-human trial of RNA vaccine for ovarian cancer

The company has received regulatory approval from the MHRA and Regional Ethics Committee to initiate its OVACT Phase I/Ib clinical trial of CryptiVax-1001, an off-the-shelf mRNA immunotherapy targeting high-grade serous ovarian cancer
Research & Development

NEUVIOR Pharmaceuticals receives Innovate UK grant to explore bio-based materials for circular pharmaceutical manufacturing

The Innovate UK feasibility grant will advance its ZYLON programme, which involves clean-chemistry lab trials exploring how bio-derived materials could replace harder-to-recycle packaging formats and reduce waste in pharmaceutical manufacturing
Subscribe now